Overview

BP101 for Adults With Female Sexual Dysfunction

Status:
Completed
Trial end date:
2019-01-23
Target enrollment:
Participant gender:
Summary
This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD). Patients will be randomized in 1:1 ratio to either BP101 or placebo arms.
Phase:
Phase 3
Details
Lead Sponsor:
Ivix LLX